URD

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on: 
수요일, 4월 24, 2024
PFS, CMO, AMF, Cash, Pancreatic cancer, Research, Webcast, Lung, RT, AACR, Lung cancer, EIB, Conference call, Annual report, NBTXR3, ESMO, Conference, Janssen, NSCLC, Monroe Dunaway Anderson, Survival, Johnson & Johnson, Research and development, OS, Therapy, Neoplasm, Clinical trial, Cancer, Esophageal cancer, Immunotherapy, MD, Administration, University, URD, Patient, NANO, MD Anderson Cancer Center, Head, Bank statement, Growth, Pharmaceutical industry

PARIS and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and reported financial results for the year ended December 31, 2023, and announced the filing of its universal registration document (URD) for the financial year ended December 31, 2023 with the French financial market authority (Autorité des marchés financiers or AMF), as well as of the Annual Report on Form 20-F for the financial year ended December 31, 2023 with the U.S. Securities and Exchange Commission (SEC).

Key Points: 
  • “2023 was an incredible year of progress for Nanobiotix and our NBTXR3 program.
  • “During 2023, we reported prolonged survival from Study 102 in head and neck cancer further reinforcing the design of our ongoing pivotal NANORAY-312 trial.
  • Cash and Cash Equivalents: As of December 31, 2023, Nanobiotix had €75.3 million in cash and cash equivalents, compared to €41.4 million as of December 31, 2022.
  • During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s year-end results and an update on business activities before taking questions from participants.

GenSight Biologics Announces the Filing of its 2023 Universal Registration Document

Retrieved on: 
목요일, 4월 18, 2024
Health, Biometrics, Health Technology, Genetics, Other Health, Optical, Biotechnology, Share repurchase, URD, AMF

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2023 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.24-0299.

Key Points: 
  • GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2023 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.24-0299.
  • The universal registration document notably includes:
    the 2023 annual financial report;
    the report on corporate governance; and
    the description of the share buyback program.
  • This universal registration document may be consulted on the Company’s website ( www.gensight-biologics.com ), “Investors” section, and on the AMF’s website ( www.amf-france.org ).

EQS-News: Abivax reports 2023 financial results and operational update

Retrieved on: 
수요일, 4월 10, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

Abivax reports 2023 financial results and operational update

Retrieved on: 
화요일, 4월 2, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

Retrieved on: 
월요일, 3월 25, 2024
Saint-Herblain, URD, VLA, Euronext Paris, File, AMF, Cryptocurrency

Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.24-0157 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC).

Key Points: 
  • Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.24-0157 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC).
  • Valneva’s 2023 Universal Registration Document – available in its entirety in French – includes the Company’s 2023 Annual Financial Report, the Company's Annual Management Report, the Board of Directors’ Corporate Governance Report and the Company’s Sustainability Report.
  • These documents are available on Valneva’s website ( https://valneva.com/investors/financial-reports/ ) and will also be available on the AMF ( www.amf-france.org/ ) and SEC ( www.sec.gov/ ) websites, respectively.
  • Hard copies of these documents may be obtained from the Company, free of charge, upon request at the following address: 6 rue Alain Bombard, 44800 Saint-Herblain, France.

GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update

Retrieved on: 
목요일, 4월 4, 2024
Health, Neurology, Genetics, Pharmaceutical, Optical, Biotechnology, PIII, URD, Three-body problem, Patient, Good manufacturing practice, Health care, EAP, Acquisition, EMA, Risk, Chapter, GMP, MHRA, DS, ATU, AMF, Good, Phase, AAP, Ethics, FDA, Amendment, AAC, Medication, Pharmaceutical industry

GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.

Key Points: 
  • GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.
  • Once the AAC/AAP program resumes, the Company estimates that the cash runway would be extended to the end of Q1 2025.
  • GenSight successfully manufactured two Drug Substance (DS) batches of LUMEVOQ® meeting Good Manufacturing Practice (GMP) standards in September and November 2023.
  • As of March 31, 2024, GenSight Biologics’ number of outstanding shares was 78,370,724 ordinary shares.

GenSight Biologics Reports Full Year 2023 Consolidated Financial Results

Retrieved on: 
금요일, 3월 22, 2024
Health, Neurology, Genetics, Pharmaceutical, Optical, Biotechnology, Control, URD, Three-body problem, Safety, Partnership, Research, CIR, ANSM, CMC, EMA, BofA Securities, Risk, Chapter, MHRA, Clinical trial, European Investment Bank, ATU, AMF, Workforce, EIB, AAP, Marketing, FDA, Amendment, AAC, Cryptocurrency

From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.

Key Points: 
  • From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.
  • The Company's general and administrative expenses also remained stable and amounted to €5.4 million in 2022 and 2023.
  • The weighted average number of shares outstanding increased from 46.3 million in 2022 to 48.3 million in 2023, thereby reducing the loss per share from (€0.54) in 2023 to (€0.60) in 2023.
  • GenSight Biologics will report its cash position as of March 31, 2024 on April 4 2024.

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

Retrieved on: 
금요일, 3월 8, 2024
DBV Technologies, Annual report, File, Form, URD, Food, DBV, Pierre Brossolette

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”).

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”).
  • These documents can be accessed on the Investors section of the Company's website at www.dbv-technologies.com .
  • In addition, the URD is available on the AMF’s website at www.amf-france.org and the Form 10-K is available on the SEC’s website at www.sec.gov .
  • Printed copies of both documents are available, free of charge, at the Company’s headquarters and registered office located at 177-181 avenue Pierre Brossolette 92120 Montrouge, France.

NMDP/Be The Match® PTCy Research Levels the Field between Matched and Mismatched Hematopoietic Cell Transplantation

Retrieved on: 
월요일, 12월 11, 2023
NMDP, Rated R, Comparison, BMT, Risk, Acute lymphoblastic leukemia, CNI, Research, Graft-versus-host disease, Hope, Calcineurin, Cyclophosphamide, HLA, Exhibition, URD, Society, GRFS, MDS, ASH, HCT, NRM, Syndrome, MMUD, GVHD, Patient, Acute myeloid leukemia, ALL, OS, AML, Senior, Dentistry

The study shows the practice-changing potential of using mismatched unrelated donors (MMUD) to expand access to all patients regardless of ancestry.

Key Points: 
  • The study shows the practice-changing potential of using mismatched unrelated donors (MMUD) to expand access to all patients regardless of ancestry.
  • “However, PTCy has transformed the allogeneic HCT landscape, enabling successful use of mismatched related and unrelated donor HCT by transcending the HLA barrier.
  • This research not only confirms the efficacy of PTCy, but also alludes to its promise to provide allogeneic HCT to essentially all patients irrespective of their ancestry.
  • The study was designed to determine if PTCy can eliminate disparities in GRFS and OS between matched (8/8) and single mismatched (7/8) URD compared to haploidentical (half matched)-related donors.

After 2 years of optimizing its online databases, Artmarket.com posts substantial Q3 2023 turnover growth: up 75%

Retrieved on: 
화요일, 11월 7, 2023
Knowledge, UI, Peter Hancock (professor), Suggestion, AMF, Fruit, RWD, Catalog, Health, History, Art market, URD, UX, Advertising, Euronext Paris, Statistics, Biography, Thierry Ehrmann, Codex, Collection, Investment, Back office, Communication, Uncertainty, Archive, COVID-19, Cryptocurrency, Video game, Industrial design, Online shopping, Auction, Book, Artprice, Art

As a result, our turnover for the 3rd quarter of 2023 has posted a 75% increase versus the year-earlier period.

Key Points: 
  • As a result, our turnover for the 3rd quarter of 2023 has posted a 75% increase versus the year-earlier period.
  • From early September 2023, the final online version of Artprice.com by Artmarket , World Leader in Art Market Information for 25 years, has become the Art Market benchmark in terms of customer experience and ergonomics.
  • In the long term, we can therefore expect significant turnover growth (due to higher traffic) and this has already been confirmed by our Q3 2023 figures which show a 75% turnover increase vs. Q3 2022.
  • With the new advertising revenue, Artprice by Artmarket expects to double its turnover in 2023/2024 versus the previous financial year.